Quick Overview
High-purity CJC-1295 without DAC (also known as Modified GRF 1-29), a synthetic growth hormone-releasing hormone (GHRH) analog synthesized specifically for in vitro laboratory research and development. Formulated as a sterile, lyophilized powder to ensure maximum stability and precision in endocrine and receptor binding assay models.
Product Description
CJC-1295 without DAC (Mod GRF 1-29) is a modified 29-amino-acid peptide analog of human growth hormone-releasing hormone (GHRH). Unlike its DAC-conjugated counterpart, this version lacks the Drug Affinity Complex, resulting in a shorter half-life that mimics natural pulsatile secretion patterns in vitro. In scientific research, CJC-1295 without DAC is extensively utilized by researchers to analyze acute GHRH receptor stimulation kinetics, pituitary response pathways, and short-term metabolic regulatory mechanisms.
Common Research Applications:
- Pulsatile Secretion Studies: Investigating short-term growth hormone release patterns and acute pituitary stimulation kinetics.
- GHRH Receptor Binding: Assessing receptor affinity and downstream cellular signaling cascades in culture models.
- Endocrine Pathway Analysis: Observing regulatory feedback dynamics and secretagogue response profiles.
- Assay Standardization: Analyzing short-half-life peptide behavior and structural stability in specialized experimental environments.
Technical Specifications
| Compound Name | CJC-1295 Without DAC (Mod GRF 1-29) |
|---|---|
| CAS Number | 863288-34-0 |
| Molecular Formula | C152H252N44O42 |
| Molecular Weight | 3367.9 g/mol |
| Peptide Sequence | Modified GHRH (1-29) Tetrasubstituted |
| Purity (HPLC) | ≥98.0% |
| Appearance | White lyophilized solid |
| Solubility | Soluble in sterile water or bacteriostatic water |
Storage and Reconstitution
To maintain peptide integrity and stability, please adhere to standard laboratory handling guidelines:
- Lyophilized Form (Dry Powder): Store desiccated at -20°C (or below) upon receipt. While stable at room temperature for brief transit periods, long-term freezing is required to prevent degradation.
- Reconstitution: Reconstitute using bacteriostatic water or sterile water for injection. Introduce the diluent carefully and gently swirl the vial until dissolved. Do not shake vigorously, as this can fracture the peptide bonds.
- Liquid Storage (Reconstituted): Once reconstituted, the solution should be stored at 2°C to 8°C (refrigerated) and utilized within 14 to 30 days. For extended experimental timelines, aliquot the solution into individual vials and freeze at -20°C to avoid repeated freeze-thaw cycles.
Regulatory & Safety Disclaimer
NOTICE TO BUYER: By purchasing this product, you legally acknowledge and agree that it is strictly for Research Use Only (RUO). It is unequivocally prohibited to be used as a drug, food additive, cosmetic, or household chemical.
- Not for Human or Animal Use: This material has not been evaluated or approved by the FDA (or any other international regulatory agency) for therapeutic, diagnostic, or clinical use.
- Qualified Personnel: This product must be handled exclusively by qualified scientific professionals in a regulated laboratory setting, utilizing standard safety and sterile protocols.
- Liability: The purchaser assumes all risks and liabilities associated with the handling, storage, and experimental application of this product.
Reviews
There are no reviews yet.